Can a blood test guide better cancer treatment after surgery?
NCT ID NCT06914011
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests whether using a blood test that detects tumor DNA can guide who needs extra therapy after esophageal cancer surgery. Participants will either receive a combination of immunotherapy (tislelizumab), chemotherapy, and radiation, or be monitored without additional treatment. The goal is to see if this personalized approach improves the chance of staying cancer-free.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tislelizumab (a type of immunotherapy) combined with chemotherapy (paclitaxel and carboplatin) and radiation
What this could lead to
If successful, this approach could help doctors decide who needs extra treatment after surgery, potentially reducing the chance of cancer returning in patients with esophageal cancer.
What could go wrong
This is an early-stage Phase 3 trial with only 172 participants, so results may not apply to everyone. The combination therapy also carries risks like side effects from chemotherapy and radiation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••